| [1] |
崔永佳，卢雯平，吴晓晴，等. 外泌体在乳腺癌内分泌耐药方面的研究现状及中药干预可能的作用机制探讨[J]. 中国医药，2022, 17(3): 326-329.
|
| [2] |
张艳，秦琴，周度金，等. 核受体超家族及其辅调节子的研究进展[J]. 局解手术学杂志，2007，3 (1): 58-59.
|
| [3] |
Lee YS, Chanda D, Sim J, et al. Structure and function of the atypical orphan nuclear receptor small heterodimer partner[J]. Int Rev Cytol, 2007, 261(7)：117-158.
|
| [4] |
Frigo DE, Bondesson M, Williams C, et al. Nuclear receptors: from molecular mechanisms to therapeutics[J]. Essays Biochem, 2021, 65(6)：847-856.
|
| [5] |
Hörlein AJ, Näär AM, Heinzel T, et al. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor [J]. Nature, 1995, 377(6548)：397-404.
|
| [6] |
Zhang Y, Hagedorn CH, Wang L, et al. Role of nuclear receptor SHP in metabolism and cancer[J]. Biochim Biophys Acta, 2011, 1812(8)：893-908.
|
| [7] |
Zhang Y, Dufau ML. Gene silencing by nuclear orphan receptors[J]. Vitam Horm, 2004, 68(4)：1-48.
|
| [8] |
Reese VC, Moore DD, McLachlan A, et al. Limited effects of bile acids and small heterodimer partner on hepatitis B virus biosynthesis in vivo[J]. J Virol, 2012, 86(5)：2760-2768.
|
| [9] |
Seol W, Choi HS, Moore DD, et al. An orphan nuclear hormone receptor that lacks a DNA binding domain and heterodimerizes with other receptors[J]. Science, 1996, 272(5266)：1336-1339.
|
| [10] |
Johansson L, Båvner A, Thomsen JS, et al. The orphan nuclear receptor SHP utilizes conserved LXXLL-related motifs for interactions with ligand-activated estrogen receptors[J]. Mol Cell Biol, 2000, 20(4)：1124-1133.
|
| [11] |
Macchiarulo A, Rizzo G, Costantino G, et al. Unveiling hidden features of orphan nuclear receptors: the case of the small heterodimer partner (SHP)[J]. J Mol Graph Model, 2006, 24(5)：362-372.
|
| [12] |
França MM, Ferraz-de-Souza B, Lerario AM, et al. POD-1/TCF21 reduces SHP expression, affecting LRH-1 regulation and cell cycle balance in adrenocortical and hepatocarcinoma tumor cells[J]. Biomed Res Int, 2015, 2015(9)：841 784.
|
| [13] |
Giordano C, Barone I, Vircillo V, et al. Activated FXR inhibits leptin signaling and counteracts tumor-promoting activities of cancer-associated fibroblasts in breast malignancy[J]. Sci Rep, 2016, 6(2)：21 782.
|
| [14] |
Swales KE, Korbonits M, Carpenter R, et al. The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression[J]. Cancer Res, 2006, 66(20)：10 120-10 126.
|
| [15] |
Wang YD, Chen WD, Moore DD, et al. FXR: a metabolic regulator and cell protector[J]. Cell Res, 2008, 18(11)：1087-1095.
|
| [16] |
Johansson L, Thomsen JS, Damdimopoulos AE, et al. The orphan nuclear receptor SHP inhibits agonist-dependent transcriptional activity of estrogen receptors ERalpha and ERbeta[J]. J Biol Chem, 1999, 274(1)：345-353.
|
| [17] |
Belkaid A, Duguay SR, Ouellette RJ, et al. 17β-estradiol induces stearoyl-CoA desaturase-1 expression in estrogen receptor-positive breast cancer cells[J]. BMC Cancer, 2015, 15：440.
|
| [18] |
Xie YB, Lee OH, Nedumaran B, et al. SMILE, a new orphan nuclear receptor SHP-interacting protein, regulates SHP-repressed estrogen receptor transactivation [J]. Biochem J, 2008, 416(3)：463-473.
|
| [19] |
Seol W, Choi HS, Moore DD, et al. An orphan nuclear hormone receptor that lacks a DNA binding domain and heterodimerizes with other receptors[J]. Science, 1996, 272(5266)：1336-1339.
|
| [20] |
Gobinet J, Auzou G, Nicolas JC, et al. Characterization of the interaction between androgen receptor and a new transcriptional inhibitor, SHP[J]. Biochemistry, 2001, 40(50)：15 369-15 377.
|
| [21] |
Zhou J, Suzuki T, Kovacic A, et al. Interactions between prostaglandin E(2), liver receptor homologue-1, and aromatase in breast cancer[J]. Cancer Res, 2005, 65(2)：657-663.
|
| [22] |
Schwaderer J, Phan TS, Glöckner A, et al. Pharmacological LRH-1/Nr5a2 inhibition limits pro-inflammatory cytokine production in macrophages and associated experimental hepatitis[J]. Cell Death Dis, 2020, 11(2)：154.
|
| [23] |
Ortlund EA, Lee Y, Solomon IH, et al. Modulation of human nuclear receptor LRH-1 activity by phospholipids and SHP[J]. Nat Struct Mol Biol, 2005, 12(4)：357-363.
|
| [24] |
Benod C, Carlsson J, Uthayaruban R, et al. Structure-based discovery of antagonists of nuclear receptor LRH-1[J]. J Biol Chem, 2013, 288(27)：19 830-19 844.
|
| [25] |
Lee YK, Moore DD. Dual mechanisms for repression of the monomeric orphan receptor liver receptor homologous protein-1 by the orphan small heterodimer partner[J]. J Biol Chem, 2002, 277(4)：2463-2467.
|
| [26] |
Chand AL, Wijayakumara DD, Knower KC, et al. The orphan nuclear receptor LRH-1 and ERα activate GREB1 expression to induce breast cancer cell proliferation[J]. PLoS One, 2012, 7(2)：e31593.
|
| [27] |
Joe AK, Arber N, Bose S, et al. Cyclin D1 overexpression is more prevalent in non-Caucasian breast cancer[J]. Anticancer Res, 2001, 21(5)：3535-3539.
|
| [28] |
Zwijsen RM, Wientjens E, Klompmaker R, et al. CDK-independent activation of estrogen receptor by cyclin D1[J]. Cell, 1997, 88(3)：405-415.
|
| [29] |
邹辣，吴绮楠. 激素受体阳性乳腺癌的内分泌治疗[J].重庆医科大学学报，2021, 46(1)：91-96.
|
| [30] |
Zou A, Lehn S, Magee N, et al. New insights into orphan nuclear receptor SHP in Liver Cancer[J]. Nucl Receptor Res, 2015, 2(8)：101 162.
|
| [31] |
Klinge CM, Jernigan SC, Risinger KE, et al. The agonist activity of tamoxifen is inhibited by the short heterodimer partner orphan nuclear receptor in human endometrial cancer cells[J]. Endocrinology, 2002, 143(3)：853-867.
|
| [32] |
Johansson L, Båvner A, Thomsen JS, et al. The orphan nuclear receptor SHP utilizes conserved LXXLL-related motifs for interactions with ligand-activated estrogen receptors[J]. Mol Cell Biol, 2000, 20(4)：1124-1133.
|
| [33] |
Gobinet J, Carascossa S, Cavaillès V, et al. SHP represses transcriptional activity via recruitment of histone deacetylases[J]. Biochemistry, 2005, 44(16)：6312-6320.
|
| [34] |
Peurala E, Koivunen P, Haapasaari KM, et al. The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer[J]. Breast Cancer Res, 2013, 15(1)：R5.
|
| [35] |
Annicotte JS, Chavey C, Servant N, et al. The nuclear receptor liver receptor homolog-1 is an estrogen receptor target gene[J]. Oncogene, 2005, 24(55)：8167-8175.
|
| [36] |
Lai CF, Flach KD, Alexi X, et al. Co-regulated gene expression by oestrogen receptor α and liver receptor homolog-1 is a feature of the oestrogen response in breast cancer cells[J]. Nucleic Acids Res, 2013, 41(22)：10 228-10 240.
|
| [37] |
Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor[J]. Cell, 1997, 89(3)：331-340.
|
| [38] |
Holder AM, Gonzalez-Angulo AM, Chen H, et al. High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients[J]. Breast Cancer Res Treat, 2013, 137(1)：319-327.
|
| [39] |
Du T, Sikora MJ, Levine KM, et al. Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer[J]. Breast Cancer Res, 2018, 20(1)：106.
|
| [40] |
赵静，张立涛，白云，等. 抑制硬脂酰辅酶A去饱和酶1表达对乳腺癌细胞增殖和周期的影响[J]. 四川大学学报(医学版), 2019, 50(4)：546-550.
|
| [41] |
Yi J, Zhu J, Wu J, et al. Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis[J]. Proc Natl Acad Sci U S A, 2020, 117(49)：31 189-31 197.
|
| [42] |
Mauvoisin D, Charfi C, Lounis AM, et al. Decreasing stearoyl-CoA desaturase-1 expression inhibits β-catenin signaling in breast cancer cells[J]. Cancer Sci, 2013, 104(1)：36-42.
|
| [43] |
Pérez-Tenorio G, Stål O. Southeast Sweden Breast Cancer Group. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients[J]. Br J Cancer, 2002, 86(4)：540-545.
|
| [44] |
孙文婧，胡曼婷，李娜，等. 乳腺癌内分泌治疗耐药及其逆转的研究进展[J].昆明医科大学学报，2021, 42(7)：143-149.
|